NCT01388959View on ClinicalTrials.gov

A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

rituximab [MabThera/Rituxan]

375 mg/m2 intravenously once a week for 4 weeks

Trial Locations (1)

31059

Toulouse

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01388959 - A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter